Cargando…

1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use

BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of...

Descripción completa

Detalles Bibliográficos
Autores principales: Eaton, Ellen, Mathews, Ronald, Lane, Peter S, Paddock, Cayce S, Rodriguez, J Martin, Taylor, Benjamin B, Saag, Michael, Kilgore, Meredith, Lee, Rachael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252732/
http://dx.doi.org/10.1093/ofid/ofy209.104
_version_ 1783373331656867840
author Eaton, Ellen
Mathews, Ronald
Lane, Peter S
Paddock, Cayce S
Rodriguez, J Martin
Taylor, Benjamin B
Saag, Michael
Kilgore, Meredith
Lee, Rachael
author_facet Eaton, Ellen
Mathews, Ronald
Lane, Peter S
Paddock, Cayce S
Rodriguez, J Martin
Taylor, Benjamin B
Saag, Michael
Kilgore, Meredith
Lee, Rachael
author_sort Eaton, Ellen
collection PubMed
description BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of stay (ALOS) without increasing readmissions. We analyzed the cost savings of the IVAT to the health system. METHODS: PWID at the University of Alabama at Birmingham (UAB) hospital with indications for prolonged IV antibiotics received IVAT to determine risk of continued IDU. “Low-risk” patients were discharged for outpatient antibiotics and addiction care; others continued inpatient antibiotics, group therapy, opioid agonist therapy (if applicable), and weekly assessment for discharge readiness. Cost of care was defined by direct costs and was obtained by querying financial accounts. RESULTS: A total of 37 pre-IVAT and 111 post-IVAT admissions (including 25 “low risk”) met study criteria. IVAT reduced ALOS by 20 days. Total direct costs per admission in the post-IVAT period were 33% lower: $26,014 versus $38,716 (Table 1). Because ALOS at UAB for all patients is 6.58 days, a 20-day ALOS reduction following IVAT creates capacity for an additional 333 patients (n = 20/6.58 × 111). CONCLUSION: IVAT for PWID allows health systems to focus inpatient resources on those at greatest risk of ongoing IVDU, creates additional inpatient capacity, and may cut hospital direct costs by one-third. DISCLOSURES: J. M. Rodriguez, finch: Research Contractor, Research support. seres: Research Contractor, Research support.
format Online
Article
Text
id pubmed-6252732
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62527322018-11-28 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use Eaton, Ellen Mathews, Ronald Lane, Peter S Paddock, Cayce S Rodriguez, J Martin Taylor, Benjamin B Saag, Michael Kilgore, Meredith Lee, Rachael Open Forum Infect Dis Abstracts BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of stay (ALOS) without increasing readmissions. We analyzed the cost savings of the IVAT to the health system. METHODS: PWID at the University of Alabama at Birmingham (UAB) hospital with indications for prolonged IV antibiotics received IVAT to determine risk of continued IDU. “Low-risk” patients were discharged for outpatient antibiotics and addiction care; others continued inpatient antibiotics, group therapy, opioid agonist therapy (if applicable), and weekly assessment for discharge readiness. Cost of care was defined by direct costs and was obtained by querying financial accounts. RESULTS: A total of 37 pre-IVAT and 111 post-IVAT admissions (including 25 “low risk”) met study criteria. IVAT reduced ALOS by 20 days. Total direct costs per admission in the post-IVAT period were 33% lower: $26,014 versus $38,716 (Table 1). Because ALOS at UAB for all patients is 6.58 days, a 20-day ALOS reduction following IVAT creates capacity for an additional 333 patients (n = 20/6.58 × 111). CONCLUSION: IVAT for PWID allows health systems to focus inpatient resources on those at greatest risk of ongoing IVDU, creates additional inpatient capacity, and may cut hospital direct costs by one-third. DISCLOSURES: J. M. Rodriguez, finch: Research Contractor, Research support. seres: Research Contractor, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6252732/ http://dx.doi.org/10.1093/ofid/ofy209.104 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Eaton, Ellen
Mathews, Ronald
Lane, Peter S
Paddock, Cayce S
Rodriguez, J Martin
Taylor, Benjamin B
Saag, Michael
Kilgore, Meredith
Lee, Rachael
1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title_full 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title_fullStr 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title_full_unstemmed 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title_short 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
title_sort 1634. a 9-point risk assessment for patients who inject drugs requiring intravenous antibiotics may allow health systems to focus inpatient resources on those at greatest risk of ongoing drug use
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252732/
http://dx.doi.org/10.1093/ofid/ofy209.104
work_keys_str_mv AT eatonellen 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT mathewsronald 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT lanepeters 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT paddockcayces 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT rodriguezjmartin 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT taylorbenjaminb 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT saagmichael 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT kilgoremeredith 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse
AT leerachael 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse